5/10
03:40 pm
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
5/9
07:06 am
mnpr
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline [Yahoo! Finance]
Low
Report
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline [Yahoo! Finance]
5/9
07:00 am
mnpr
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
Low
Report
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
4/18
08:04 am
mnpr
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting [Yahoo! Finance]
Neutral
Report
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting [Yahoo! Finance]
4/18
08:00 am
mnpr
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
Medium
Report
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
4/16
08:20 am
mnpr
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings [Yahoo! Finance]
Low
Report
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings [Yahoo! Finance]
4/16
08:00 am
mnpr
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
Low
Report
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
4/11
08:06 am
mnpr
Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Jonestrading from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
High
Report
Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Jonestrading from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
4/10
08:13 am
mnpr
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients [Yahoo! Finance]
Medium
Report
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients [Yahoo! Finance]
4/10
08:00 am
mnpr
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
High
Report
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
4/4
11:39 am
mnpr
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
4/3
01:21 pm
mnpr
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy [Yahoo! Finance]
3/28
07:09 am
mnpr
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments [Yahoo! Finance]
Medium
Report
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments [Yahoo! Finance]
3/28
07:00 am
mnpr
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Medium
Report
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
3/5
07:11 am
mnpr
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program [Yahoo! Finance]
Medium
Report
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program [Yahoo! Finance]
3/5
07:00 am
mnpr
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
Medium
Report
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
2/27
07:12 am
mnpr
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial [Yahoo! Finance]
Medium
Report
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial [Yahoo! Finance]
2/27
07:00 am
mnpr
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
Medium
Report
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
2/27
05:55 am
mnpr
Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Watching Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation [Yahoo! Finance]
2/23
12:43 pm
mnpr
CPOP, PMEC and ARIZ among mid-day movers [Seeking Alpha]
Low
Report
CPOP, PMEC and ARIZ among mid-day movers [Seeking Alpha]
2/22
07:06 am
mnpr
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers [Yahoo! Finance]
High
Report
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers [Yahoo! Finance]
2/22
07:00 am
mnpr
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
High
Report
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
2/20
08:12 am
mnpr
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers [Yahoo! Finance]
High
Report
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers [Yahoo! Finance]
2/20
08:00 am
mnpr
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
High
Report
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers